Tumor redox heterogeneity-responsive nanoparticles for enhanced antitumor efficacy through combining chemo/chemodynamic therapy.

ABSTRACT: Cancer represents a significant global health threat, and traditional chemotherapy (CT) often encounters limitations in efficacy due to systemic toxic side effects and tumor heterogeneity. The combination of chemodynamic Therapy (CDT) and CT offers a potential solution to overcome the constraints of single-agent therapies. However, many CT/CDT collaborative systems have critical shortcomings, including insufficient active targeting capabilities, depletion of H₂O₂ substrates leading to a reduction in CDT effectiveness, and the heterogeneity of redox within tumor cells, which can result ultimately limit overall efficacy. This study developed a redox heterogeneity-responsive CT/CDT nanoparticle, named HFMD, with the goal of overcoming the limitations associated with trad

SUBMITTER: Cui S 

PROVIDER: S-EPMC12702408 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature